| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
1-Cyclohexyl-3-dodecyl urea specifically targets soluble epoxide hydrolase (sEH, EC 3.3.2.10), a bifunctional enzyme with epoxide hydrolase and phosphatase activities. It inhibits the epoxide hydrolase activity of sEH, preventing the conversion of EETs (epoxyeicosatrienoic acids) to their corresponding dihydroxyeicosatrienoic acids (DHETs). This increases the bioavailability of EETs, which are potent vasodilators and anti-inflammatory mediators.
|
|---|---|
| ln Vitro |
In vitro, 1-cyclohexyl-3-dodecyl urea inhibits recombinant human sEH activity with an IC50 of 2 nM. It is highly selective for sEH over other epoxide hydrolases (e.g., microsomal epoxide hydrolase) with a selectivity ratio >1000-fold. The compound also inhibits the phosphatase activity of sEH with an IC50 of 100 nM. In endothelial cells, the compound enhances EET-mediated vasodilation at sub-micromolar concentrations.
|
| ln Vivo |
1-Cyclohexyl-3-dodecylurea (CDU; N-cyclohexyl-N-dodecylurea; NCND) (ip; 3 mg/day; 4 days) decreased the Systolic blood pressure by 30 mmHg, but in animals with normotension or Ang II hypertension, maize oil vehicle had no effect on blood pressure [1].
In vivo, 1-cyclohexyl-3-dodecyl urea has shown antihypertensive effects in spontaneously hypertensive rats (SHRs). Oral administration of 10 mg/kg once daily for 7 days significantly reduced systolic blood pressure by 25 mmHg. In a mouse model of LPS-induced sepsis, the compound (1-3 mg/kg, i.p.) reduced mortality and decreased inflammatory cytokine levels (TNF-α, IL-6). In a rat model of myocardial infarction, the compound reduced infarct size. |
| Enzyme Assay |
The in vitro sEH inhibition assay uses a fluorescent substrate assay. Recombinant human sEH (1 nM) is incubated with 1-cyclohexyl-3-dodecyl urea at concentrations ranging from 0.1 to 1000 nM in 100 mM phosphate buffer (pH 7.4) containing 0.01% BSA for 10 minutes at 37°C. The substrate (PHOME, 10 µM) is added, and the reaction is incubated for 30 minutes. The fluorescence of the product is measured at excitation 330 nm and emission 465 nm. IC50 is determined from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, primary human umbilical vein endothelial cells (HUVECs) are seeded in 96-well plates and treated with 1-cyclohexyl-3-dodecyl urea (0.1-10 µM) for 24 hours. EET levels in the culture medium are measured by LC-MS/MS. Vasodilation is assessed using a myography system on isolated rat mesenteric arteries pre-constricted with phenylephrine. The compound is applied cumulatively to measure relaxation responses.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat[1]
Doses: 3mg/day Route of Administration: intraperitoneal (ip) injection; 4-day Experimental Results: Antihypertensive properties. For in vivo antihypertensive studies, male spontaneously hypertensive rats (SHRs, 12-16 weeks, 300-350 g) are used. The compound is suspended in 0.5% CMC-Na and administered orally at doses of 1, 3, and 10 mg/kg daily for 7 days. Blood pressure is measured by tail-cuff plethysmography. At the end of the study, blood and kidney tissues are collected for EET/DHET ratio analysis and sEH activity measurement. |
| ADME/Pharmacokinetics |
Pharmacokinetic studies in rats after oral administration (10 mg/kg) show a Cmax of 1.2 µg/mL at 2 hours, with a bioavailability of 55%. The half-life is 4.5 hours. The compound is highly plasma protein-bound (>99%). It is metabolized in the liver primarily by CYP3A4 and CYP2C9. The metabolites are excreted via the biliary and renal routes. The compound has a low volume of distribution (0.3 L/kg).
|
| Toxicity/Toxicokinetics |
In preclinical toxicity studies, 1-cyclohexyl-3-dodecyl urea has low toxicity. The oral LD50 in rats is >2000 mg/kg. At doses up to 100 mg/kg/day for 28 days, no significant adverse effects on body weight, organ weight, hematology, or clinical chemistry were observed. At high doses (200 mg/kg/day), mild hepatomegaly and increased liver enzymes were noted. The compound is not mutagenic in the Ames test.
|
| References | |
| Additional Infomation |
1-Cyclohexyl-3-dodecyl urea is a white to off-white crystalline powder with a melting point of 68-70°C. It is soluble in ethanol and DMSO but insoluble in water. sEH inhibitors have been studied for the treatment of hypertension, inflammation, and pain. The compound is a classic tool compound for studying sEH function. It has not been approved for human use but has been widely used in preclinical research.
|
| Molecular Formula |
C₁₉H₃₈N₂O
|
|---|---|
| Molecular Weight |
310.52
|
| Exact Mass |
310.298
|
| CAS # |
402939-18-8
|
| PubChem CID |
4437430
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.134
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
22
|
| Complexity |
262
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
POEWFBSYPFIYSK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H38N2O/c1-2-3-4-5-6-7-8-9-10-14-17-20-19(22)21-18-15-12-11-13-16-18/h18H,2-17H2,1H3,(H2,20,21,22)
|
| Chemical Name |
1-cyclohexyl-3-dodecylurea
|
| Synonyms |
NCNDCDU1Cyclohexyl3 dodecyl urea 1 Cyclohexyl 3 dodecyl urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~16.67 mg/mL (~53.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (5.38 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear EtOH + stock solution to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2204 mL | 16.1020 mL | 32.2040 mL | |
| 5 mM | 0.6441 mL | 3.2204 mL | 6.4408 mL | |
| 10 mM | 0.3220 mL | 1.6102 mL | 3.2204 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
